Opsumit Label And Pricing Suggest Actelion’s Gamble Ready To Pay Off
Executive Summary
Actlelion is banking on labeling advantages and strategic pricing to propel sales of its new drug for pulmonary arterial hypertension, Opsumit, even after its best-selling PAH drug, Tracleer, goes generic.